ARCHIVES

Ibrutinib Increases OS, PFS Versus Ofatumumab in Phase III

This article is from The Cancer Letter archive.

Vol. 37 No. 6 | June 27, 2014

Download PDF Visit The Full Archive

Related Articles

In Brief: David Kessler Nominated For FDA; Salahuddin Sentenced to Research; B.J. Kennedy Honored

October 26, 1990

Cooperative Group Leadership Changes: Decosse Heads CCIRC, Hoogstraten Chairmen’s Committee

July 8, 1977

LAK –IL-2 Studies Continue, Moertel Editorial Blasted

March 13, 1987

Prostate Cancer: NIH Pans To Ramp Up Prostate Cancer Research Funding

June 25, 1999

Peers Puzzled By Herberman’s Stance On Cell Phones While Believers Rally.

August 1, 2008

Upton Says He’s Still Undecided About Leaving NCI

September 28, 1979